Literature DB >> 12748804

[Photodynamic therapy: extended indication].

R Müller-Velten1, St Michels, U Schmidt-Erfurth, H Laqua.   

Abstract

OBJECTIVE: Evaluation of efficacy of photodynamic therapy (PDT) for classic choroidal neovascularization (CNV) beyond the common indication.
METHODS: A group of 256 patients was treated with photodynamic therapy from January to December 2000. Ten of these patients had a predominantly classic CNV due to angioid streaks (5), parafoveal telangiectasia (2), or chorioretinitis (3). In two patients an idiopathic origin of the CNV was presumed. Another 21 patients showed a juxtafoveal classic membrane (12) or a recurrence after laser photocoagulation (9). Visual acuity was evaluated, also in correlation to age and CNV size. Continuous follow-up of CNV and leakage size was performed with fluorescein angiography.
RESULTS: Overall 85% of the patients showed visual stabilization or improvement during an average observation period of 10.5 months. A correlation was found between age and visual improvement favoring younger patients; however, no correlation was found between visual improvement and CNV size. CNV and leakage size decreased moderately over the 9-month follow-up from 1.81/3.45 mm(2) to 1.61/2.60 mm(2).
CONCLUSION: PDT shows efficacy for classic choroidal neovascularization beyond the common indication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748804     DOI: 10.1007/s00347-002-0723-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  7 in total

1.  [Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. Two-year results].

Authors:  J Wachtlin; A Wehner; H Heimann; M H Foerster
Journal:  Ophthalmologe       Date:  2004-05       Impact factor: 1.059

2.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

Review 3.  [Photodynamic therapy in AMD. Strategy for indication].

Authors:  D Pauleikhoff; G Spital
Journal:  Ophthalmologe       Date:  2004-12       Impact factor: 1.059

4.  Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.

Authors:  Michael Voelker; Faik Gelisken; Focke Ziemssen; Joachim Wachtlin; Salvatore Grisanti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-12       Impact factor: 3.117

5.  Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks.

Authors:  Heinrich Heimann; Faik Gelisken; Joachim Wachtlin; Andreas Wehner; Michael Völker; Michael H Foerster; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-10       Impact factor: 3.117

6.  [Transient visual decrease after photodynamic therapy].

Authors:  S Mennel; N Hausmann; C H Meyer; S Hörle; S Peter
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

7.  [Photodynamic therapy with verteporfin for uveal melanoma].

Authors:  J Wachtlin; N E Bechrakis; M H Foerster
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.